PharmaTimes are excited to announce the launch of the Medical & Scientific Excellence Awards for the second year

Following on from the success of the inaugural PharmaTimes Medical & Scientific Excellence Awards, the 2019 competition is now open for entry – showcasing the very best professionals within medical affairs.

Read on PharmaTimes

LifeArc inks pain medicine development deal with Uni of Kent

 A minimum of two to three years’ work will be required before any small-molecule candidates are ready to enter clinical development.

Read on PharmaTimes

Teva abandons Ajovy trial for cluster headaches

 A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.

Read on PharmaTimes

FDA orphan drug designation granted for Autolus’ acute lymphoblastic leukemia drug

 There will be an estimated 5,930 new cases of ALL and an estimated 1,500 related deaths in 2019.

Read on PharmaTimes

Skyrizi gets US approval for psoriasis

 The indication is for adults who are candidates for systemic therapy or phototherapy.

Read on PharmaTimes

1 2 3

Top of page

Industry News

Following on from the success of the inaugural PharmaTimes Medical & Scientific Excellence Awards, the 2019 competition is now open...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us